GlassScriptPhysician profile
Alyssa Taft
NPI 1487138590
$7,867.27
in general payments reported to CMS, 2019-2025
41 companies · $1,507 in 2025
The $1,507 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,206 · 2022: $1,798 · 2023: $1,579 · 2024: $1,777 · 2025: $1,507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,763 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,763.11 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $1,666.75 | 2023-2025 | Korlym |
| Glaxosmithkline, LLC. | $908.65 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $893.48 | 2021-2025 | |
| Novo Nordisk INC | $499.25 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $478.51 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Astellas Pharma US INC | $405.81 | 2021-2023 | Veozah |
| Amgen INC. | $384.95 | 2021-2025 | Otezla, Repatha, Evenity |
| Otsuka America Pharmaceutical, INC. | $276.36 | 2021-2025 | Rexulti, Nuedexta |
| Bayer Healthcare Pharmaceuticals INC. | $240.40 | 2022-2024 | |
| Pfizer INC. | $197.29 | 2021-2025 | |
| Daiichi Sankyo INC. | $187.00 | 2021-2024 | Injectafer |
| Merck Sharp & Dohme LLC | $183.71 | 2021-2025 | Verquvo, Lagevrio, Belsomra |
| Electromed, INC. | $170.50 | 2022 | |
| Esperion Therapeutics, INC. | $155.55 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $150.36 | 2021-2024 | Xifaxan, Trulance |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $143.56 | 2022 | |
| Novartis Pharmaceuticals Corporation | $117.63 | 2021-2024 | |
| Axsome Therapeutics, INC. | $89.01 | 2024 | Auvelity |
| Mylan Specialty L.P. | $77.72 | 2022-2023 | Yupelri |
| Neurocrine Biosciences, INC. | $75.64 | 2022-2023 | Ongentys, Ingrezza |
| Lilly USA, LLC | $68.89 | 2022-2024 | Jardiance, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.85 | 2021-2023 | Synjardy, Jardiance |
| Exact Sciences Corporation | $49.17 | 2023-2024 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.87 | 2023-2025 | Caplyta |
| Boston Scientific Corporation | $33.56 | 2022-2024 | Watchman Flx |
| Lundbeck LLC | $31.99 | 2024-2025 | Rexulti |
| Ardelyx, INC. | $25.24 | 2024 | Ibsrela |
| Ucb, INC. | $23.76 | 2023 | Nayzilam |
| Aimmune Therapeutics, INC. | $21.51 | 2024 | |
| Amarin Pharma, INC. | $20.27 | 2021 | |
| Abbott Laboratories | $20.19 | 2023 | Freestyle Libre 2 |
| Neurelis, INC. | $19.24 | 2023 | Valtoco |
| Smith+Nephew, INC. | $18.91 | 2022 | |
| Eisai INC. | $18.00 | 2021 | |
| Corium, LLC | $17.75 | 2023 | Azstarys |
| Ferring Pharmaceuticals INC. | $17.26 | 2023 | Rebyota |
| Sanofi-Aventis U.S. LLC | $16.74 | 2024 | |
| Phathom Pharmaceuticals, INC. | $14.00 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $13.87 | 2022 | |
| Biogen, INC. | $13.69 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Taft listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.